SCHEMBL4107368

SCHEMBL4107368

CCN(CC)c1ccc(NC(=S)NCCN(CCN2CCCC2)C(=O)Nc2ccc(C(F)(F)F)cc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ EPHX2 P34913 4/20 0.47
▸ HTT P42858 2/20 0.46
▸ LMNA P02545 2/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ CDK1 P06493 1/20 0.43
▸ ACHE P22303 1/20 0.41
▸ MCHR1 Q99705 1/20 0.41
▸ FPR3 P25089 2/20 0.40
▸ FPR2 P25090 2/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ TSHR P16473 1/20 0.40
▸ GAA P10253 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ THRB P10828 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4108251 0.86 EPHX2 (0.52) EPHX2MEN1KMT2AMCHR1KDM4E
SCHEMBL4120523 0.85 MCHR1 (0.53) HTTLMNAMEN1KMT2ASMN1; SMN2
SCHEMBL4107371 0.84 EPHX2 (0.45) EPHX2HTTMEN1KMT2AKDM4E
SCHEMBL4123912 0.83 EPHX2 (0.61) EPHX2MEN1KMT2A
SCHEMBL4114315 0.80 EPHX2 (0.50) EPHX2ACHEFPR3FPR2KDM4E
SCHEMBL4119717 0.79 EPHX2 (0.57) EPHX2MEN1KMT2A
SCHEMBL4124304 0.79 MEN1 (0.58) EPHX2MEN1KMT2A
SCHEMBL4113123 0.79 CNR1 (0.60) EPHX2MEN1KMT2ASMN1; SMN2MAPT
SCHEMBL4107145 0.79 CNR1 (0.60) EPHX2MEN1KMT2ASMN1; SMN2MAPT
SCHEMBL4125793 0.78 EPHX2 (0.53) EPHX2LMNASMN1; SMN2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090118330-A1 Diurea derivatives ACTIVE BIOTECH AB (SE) 2009-05-07 — — US disclosed
EP-1711175-A1 DIUREA DERIVATIVES Active Biotech AB (SE) 2006-10-18 — — EP disclosed
WO-2005074919-A1 DIUREA DERIVATIVES ACTIVE BIOTECH AB (SE) 2005-08-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118330-A1 Diurea derivatives IL2, CASP2, MAVS EPHX2 1614/4885HTT 3669/4885LMNA 3428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback